Närvänen O, Erkkilä A, Ylä-Herttuala S
A. I.Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland.
Free Radic Biol Med. 2001 Sep 15;31(6):769-77. doi: 10.1016/s0891-5849(01)00636-0.
Autoantibodies against oxidized LDL (oxLDL) have been measured in many laboratories. Comparison of data between laboratories is difficult because of methodological variations and differences in the expression of results. We have optimized an enzyme immunoassay (EIA), which measures autoantibodies against oxLDL and evaluated the effect on results of different ways of expressing the data. Optimized conditions were as follows: coating concentration 2 microg/ml of LDL on polysorp plates, 1% human serum albumin (HSA) as a blocking agent, sample dilution 1:50, conjugate dilution 1:8000, and 0.2% HSA in sample and conjugate diluents. The amount of autoantibodies expressed as ratios between oxLDL and native LDL (natLDL), as titers against oxLDL or as differences between binding to oxLDL and natLDL showed significant differences among groups of coronary heart disease (CHD) patients with different diagnosis or treatment procedures. However, there were no differences among the groups when the results were expressed as the ratio between antibody titer against oxLDL and a standard serum (oxLDL/stand). After standardization oxLDL autoantibody test may become a useful tool for analysis of the risk for CHD.
许多实验室都对氧化型低密度脂蛋白（oxLDL）自身抗体进行了检测。由于方法学差异和结果表达的不同，各实验室间的数据比较存在困难。我们优化了一种酶免疫测定法（EIA），用于检测抗oxLDL自身抗体，并评估了不同数据表达方式对结果的影响。优化条件如下：在多聚吸附板上以2微克/毫升的低密度脂蛋白（LDL）包被浓度，用1%人血清白蛋白（HSA）作为封闭剂，样本稀释度为1:50，结合物稀释度为1:8000，样本和结合物稀释液中含0.2% HSA。以oxLDL与天然LDL（natLDL）的比值、抗oxLDL的滴度或与oxLDL和natLDL结合的差异来表示的自身抗体量，在不同诊断或治疗程序的冠心病（CHD）患者组间显示出显著差异。然而，当结果以抗oxLDL抗体滴度与标准血清的比值（oxLDL/stand）表示时，各组间并无差异。标准化后，oxLDL自身抗体检测可能成为分析冠心病风险的有用工具。
